H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT

Core Viewpoint - Acrivon Therapeutics, Inc. (NASDAQ:ACRV) is highlighted as a promising investment opportunity due to its strong recent performance and significant upside potential, particularly driven by advancements in its clinical pipeline [1]. Group 1: Analyst Coverage and Price Target - H.C. Wainwright initiated coverage on Acrivon Therapeutics with a "Buy" rating and a price target of $19, reflecting a positive outlook based on the company's pipeline developments, especially the ACR-368 Phase 2b trial [2]. - The inclusion of a third cohort in the ACR-368 trial is expected to enhance enrollment and overall response rates, particularly for patients with less prior treatment, thereby improving market positioning [2]. Group 2: Financial Performance - In Q3 2025, Acrivon reported a net loss of $18.2 million, an improvement from a loss of $22.4 million in the same quarter the previous year [3]. - R&D expenses decreased from $18.9 million to $13.6 million, indicating a strategic focus on endometrial cancer [3]. - The company ended the quarter with cash reserves of $134.4 million, which is projected to fund operations into Q2 2027 [3]. Group 3: Company Overview - Acrivon Therapeutics is a clinical-stage biopharmaceutical company that develops precision medicines utilizing its Generative Phosphoproteomics AP3 platform to create targeted treatments [4].